Company / Revenue
Tvardi Therapeutics, Inc. Revenue History
FY2015-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Revenue
$41.9M
FY2024
5-year range
$13.5M / $135.1M
FY2020-FY2024
Trend
+81.8%
vs FY2023
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Revenue has fluctuated over the past 10 years, ranging from $86,000 in FY2018 to $135M in FY2022.
Based on SEC 10-K filings.
$42M in FY2024 with a 5-year CAGR of +115.0%.
Declined from $135M to $42M over the past 2 years.
Revenue over time
Growth rates
- 3-Year CAGR
- +28.2%
- 5-Year CAGR
- +115.0%
- 10-Year CAGR
- -
Key checks
Key Insights
- 5-year CAGR of +115.0%, indicating consistent growth.
- In FY2024, revenue increased 81.8% year-over-year.
- Peak revenue was recorded in FY2022.
- Lowest revenue in the period was in FY2018.
Company context
Key Data Points
- Altman Z-Score -6.41 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | RevenueValue | YoY GrowthYoY |
|---|---|---|
| FY2024 | $41.9M | +81.8% |
| FY2023 | $23.0M | -83.0% |
| FY2022 | $135.1M | +579.3% |
| FY2021 | $19.9M | +47.6% |
| FY2020 | $13.5M | +1378.5% |
| FY2019 | $911.0K | +959.3% |
| FY2018 | $86.0K | -97.7% |
| FY2017 | $3.8M | +19.7% |
| FY2016 | $3.2M | -73.4% |
| FY2015 | $12.0M | +905.4% |
As of FY2024 · SEC 10-K · Updated Jun 28, 2026